{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:25:47Z","timestamp":1792009547744,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Non-small cell lung cancer (NSCLC) with PIK3CA mutations demonstrates significant challenges in treatment due to enhanced bone metastasis and immune checkpoint resistance. This study investigates the efficacy of tumor-targeting peptide 1-modified cancer stem cell-derived extracellular vesicles (TMTP1-TSRP-EVs) in reshaping the tumor microenvironment and reversing immune checkpoint resistance in NSCLC. By integrating TMTP1-TSRP into EVs, we aim to specifically deliver therapeutic agents to NSCLC cells, focusing on inhibiting the PI3K\/Akt\/mTOR pathway, a crucial driver of oncogenic activity and immune evasion in PIK3CA-mutated cells. Our comprehensive in vitro and in vivo analyses show that TMTP1-TSRP-EVs significantly inhibit tumor growth, reduce PD-L1 expression, and enhance CD8<jats:sup>+<\/jats:sup> T cell infiltration, effectively reversing the immune-suppressive microenvironment. Moreover, the in vivo models confirm that our approach not only suppresses bone metastases but also overcomes primary resistance to immune checkpoint inhibitors by modulating the expression of key immunological markers. These findings suggest that targeted delivery of TMTP1-TSRP-EVs could provide a novel therapeutic strategy for treating PIK3CA-mutant NSCLC, offering significant improvements over traditional therapies by directly targeting the molecular pathogenesis of tumor resistance and metastasis.<\/jats:p>","DOI":"10.1038\/s41419-025-07685-y","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:40:24Z","timestamp":1746556824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC"],"prefix":"10.1038","volume":"16","author":[{"given":"Liwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanghesi","family":"Wuyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geqi","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-3697","authenticated-orcid":false,"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"7685_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105656","volume":"169","author":"Z-B Jiang","year":"2021","unstructured":"Jiang Z-B, Xu C, Wang W, Zhang Y-Z, Huang J-M, Xie Y-J, et al. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells. Pharmacol Res. 2021;169:105656.","journal-title":"Pharmacol Res"},{"key":"7685_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.34127","volume":"151","author":"KY Wong","year":"2022","unstructured":"Wong KY, Cheung AH, Chen B, Chan WN, Yu J, Lo KW, et al. Cancer-associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications. Int J Cancer. 2022;151:1195\u2013215.","journal-title":"Int J Cancer"},{"key":"7685_CR3","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s12602-023-10130-1","volume":"16","author":"H-H Yu","year":"2023","unstructured":"Yu H-H, Wu L-Y, Hsu P-L, Lee C-W, Su B-C. Marine antimicrobial peptide epinecidin-1 inhibits proliferation induced by lipoteichoic acid and causes cell death in non-small cell lung cancer cells via mitochondria damage. Probiotics Antimicrob Proteins. 2023;16:1724\u201333.","journal-title":"Probiotics Antimicrob Proteins"},{"key":"7685_CR4","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1158\/0008-5472.CAN-20-0141","volume":"80","author":"I Pulido","year":"2020","unstructured":"Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, et al. Endothelin-1\u2013mediated drug resistance in EGFR-mutant non-small cell lung carcinoma. Cancer Res. 2020;80:4224\u201332.","journal-title":"Cancer Res"},{"key":"7685_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1039\/C7LC01224A","volume":"18","author":"X Yang","year":"2018","unstructured":"Yang X, Li K, Zhang X, Liu C, Guo B, Wen W, et al. Nanofiber membrane supported lung-on-a-chip microdevice for anti-cancer drug testing. Lab Chip. 2018;18:486\u201395.","journal-title":"Lab Chip"},{"key":"7685_CR6","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.829451.","DOI":"10.3389\/fimmu.2022.829451"},{"key":"7685_CR7","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.7150\/ijbs.70958","volume":"18","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, et al. VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci. 2022;18:3845\u201358.","journal-title":"Int J Biol Sci"},{"key":"7685_CR8","doi-asserted-by":"publisher","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","DOI":"10.1038\/s41408-021-00459-7"},{"key":"7685_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845\u2013865.e7.","journal-title":"Cancer Cell"},{"key":"7685_CR10","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.927153.","DOI":"10.3389\/fimmu.2022.927153"},{"key":"7685_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.17219\/acem\/126298","volume":"29","author":"J Saetang","year":"2020","unstructured":"Saetang J, Chonpathompikunlert P, Sretrirutchai S, Roongsawang N, Kayasut K, Voravuthikunchai SP, et al. Anti-cancer effect of engineered recombinant interleukin 18. Adv Clin Exp Med. 2020;29:1135\u201343.","journal-title":"Adv Clin Exp Med"},{"key":"7685_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"key":"7685_CR13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"7685_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"7685_CR15","doi-asserted-by":"publisher","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","DOI":"10.1186\/s12943-023-01827-6"},{"key":"7685_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"key":"7685_CR17","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani C, Miricescu D, Stanescu-Spinu I-I, Nica RI, Greabu M, Totan AR, et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? IJMS. 2021;22:10260.","journal-title":"IJMS"},{"key":"7685_CR18","doi-asserted-by":"publisher","unstructured":"Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/s13023-021-01929-8.","DOI":"10.1186\/s13023-021-01929-8"},{"key":"7685_CR19","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3390\/ijms25031848","volume":"25","author":"D-T Morgos","year":"2024","unstructured":"Morgos D-T, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S, et al. Targeting PI3K\/AKT\/mTOR and MAPK signaling pathways in gastric cancer. IJMS. 2024;25:1848.","journal-title":"IJMS"},{"key":"7685_CR20","doi-asserted-by":"publisher","first-page":"e0295813","DOI":"10.1371\/journal.pone.0295813","volume":"19","author":"R Guan","year":"2024","unstructured":"Guan R, Kang Z, Li L, Yan X, Gao T. PIK3CA regulates development of diabetes retinopathy through the PI3K\/Akt\/mTOR pathway. PLoS ONE. 2024;19:e0295813.","journal-title":"PLoS ONE"},{"key":"7685_CR21","doi-asserted-by":"publisher","unstructured":"Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M et al. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-22619-w.","DOI":"10.1038\/s41467-021-22619-w"},{"key":"7685_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.bulcan.2020.07.007","volume":"107","author":"P Corbaux","year":"2020","unstructured":"Corbaux P, Sabatier R. Nouvelles AMMs au niveau europ\u00e9en : alp\u00e9lisib \u2013 cancer du sein RH+\/HER2\u2212 m\u00e9tastatique avec mutation PIK3CA. Bull du Cancer. 2020;107:959\u201360.","journal-title":"Bull du Cancer"},{"key":"7685_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/s41418-023-01209-x","volume":"30","author":"B Ducarouge","year":"2023","unstructured":"Ducarouge B, Redavid A-R, Victoor C, Chira R, Fonseca A, Hervieu M, et al. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. Cell Death Differ. 2023;30:2201\u201312.","journal-title":"Cell Death Differ"},{"key":"7685_CR24","doi-asserted-by":"publisher","unstructured":"Lim JR, Mouawad J, Gorton OK, Bubb WA, Kwan AH. Cancer stem cell characteristics and their potential as therapeutic targets. Med Oncol. 2021. https:\/\/doi.org\/10.1007\/s12032-021-01524-8.","DOI":"10.1007\/s12032-021-01524-8"},{"key":"7685_CR25","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1007\/s00432-021-03793-2","volume":"147","author":"X Lai","year":"2021","unstructured":"Lai X, Guo Y, Chen M, Wei Y, Yi W, Shi Y, et al. Caveolin1: its roles in normal and cancer stem cells. J Cancer Res Clin Oncol. 2021;147:3459\u201375.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7685_CR26","doi-asserted-by":"publisher","unstructured":"Weng Z, Zhang B, Wu C, Yu F, Han B, Li B et al. Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01141-y.","DOI":"10.1186\/s13045-021-01141-y"},{"key":"7685_CR27","doi-asserted-by":"publisher","unstructured":"Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2021. https:\/\/doi.org\/10.1186\/s12943-022-01650-5.","DOI":"10.1186\/s12943-022-01650-5"},{"key":"7685_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","volume":"41","author":"L Barthel","year":"2021","unstructured":"Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2021;41:53\u201375.","journal-title":"Cancer Metastasis Rev"},{"key":"7685_CR29","doi-asserted-by":"crossref","unstructured":"M\u00fcller Bark J, Kulasinghe A, Amen\u00e1bar JM, Punyadeera C. Exosomes in cancer. Adv Clin Chem. 2021:101:1\u201340.","DOI":"10.1016\/bs.acc.2020.06.006"},{"key":"7685_CR30","doi-asserted-by":"publisher","unstructured":"Wu J, Ma Y, Chen Y. Extracellular vesicles and COPD: foe or friend? J Nanobiotechnol. 2023. https:\/\/doi.org\/10.1186\/s12951-023-01911-5.","DOI":"10.1186\/s12951-023-01911-5"},{"key":"7685_CR31","doi-asserted-by":"publisher","unstructured":"Das Gupta A, Krawczynska N, Nelson ER. Extracellular vesicles\u2014the next frontier in endocrinology. Endocrinology. 2021. https:\/\/doi.org\/10.1210\/endocr\/bqab133.","DOI":"10.1210\/endocr\/bqab133"},{"key":"7685_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.apsb.2020.12.014","volume":"11","author":"Q Hu","year":"2021","unstructured":"Hu Q, Lyon CJ, Fletcher JK, Tang W, Wan M, Hu TY. Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses. Acta Pharm Sin B. 2021;11:1493\u2013512.","journal-title":"Acta Pharm Sin B"},{"key":"7685_CR33","doi-asserted-by":"publisher","unstructured":"Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022. https:\/\/doi.org\/10.1186\/s12964-022-00959-4.","DOI":"10.1186\/s12964-022-00959-4"},{"key":"7685_CR34","doi-asserted-by":"publisher","first-page":"10572","DOI":"10.3390\/ijms221910572","volume":"22","author":"MG Scioli","year":"2021","unstructured":"Scioli MG, Terriaca S, Fiorelli E, Storti G, Fabbri G, Cervelli V, et al. Extracellular vesicles and cancer stem cells in tumor progression: new therapeutic perspectives. IJMS. 2021;22:10572.","journal-title":"IJMS"},{"key":"7685_CR35","doi-asserted-by":"publisher","unstructured":"Wang Z, Qu T, Zhang Z, Zeng F, Song H, Zhang K et al. A transformable specific-responsive peptide for one-step synergistic therapy of bladder cancer. Small. 2024. https:\/\/doi.org\/10.1002\/smll.202310416.","DOI":"10.1002\/smll.202310416"},{"key":"7685_CR36","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1073\/pnas.1202810109","volume":"109","author":"H Jo","year":"2012","unstructured":"Jo H, Mondal S, Tan D, Nagata E, Takizawa S, Sharma AK, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci USA. 2012;109:10581\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7685_CR37","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1039\/C6TB00268D","volume":"4","author":"T Lu","year":"2016","unstructured":"Lu T, Li J, Qian S, Cao H, Ning C, Liu X. Enhanced osteogenic and selective antibacterial activities on micro-\/nano-structured carbon fiber reinforced polyetheretherketone. J Mater Chem B. 2016;4:2944\u201353.","journal-title":"J Mater Chem B"},{"key":"7685_CR38","doi-asserted-by":"publisher","unstructured":"Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 dampens CD8+ T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01032.","DOI":"10.3389\/fimmu.2019.01032"},{"key":"7685_CR39","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.18632\/aging.103231","volume":"12","author":"G Jiang","year":"2020","unstructured":"Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, et al. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging. 2020;12:11466\u201384.","journal-title":"Aging"},{"key":"7685_CR40","doi-asserted-by":"publisher","unstructured":"Tao X, Du R, Guo S, Feng X, Yu T, OuYang Q et al. PGE2-EP3 axis promotes brown adipose tissue formation through stabilization of WTAP RNA methyltransferase. EMBO J. 2022. https:\/\/doi.org\/10.15252\/embj.2021110439.","DOI":"10.15252\/embj.2021110439"},{"key":"7685_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s12272-012-0516-x","volume":"35","author":"HS Song","year":"2012","unstructured":"Song HS, Choi MY, Ko MS, Jeong JM, Kim YH, Jang BH, et al. Competitive inhibition of cytosolic Ca2+-dependent phospholipase A2 by acteoside in RBL-2H3 cells. Arch Pharm Res. 2012;35:905\u201310.","journal-title":"Arch Pharm Res"},{"key":"7685_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2009.04.030","volume":"138","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Chiang AC, Zhang XH-F, Kim JY, Kris MG, Ladanyi M, et al. WNT\/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138:51\u201362.","journal-title":"Cell"},{"key":"7685_CR43","doi-asserted-by":"publisher","unstructured":"Liu F, Wu Q, Han W, Laster K, Hu Y, Ma F et al. Targeting integrin \u03b1v\u03b23 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. Clin Transl Med. 2021. https:\/\/doi.org\/10.1002\/ctm2.548.","DOI":"10.1002\/ctm2.548"},{"key":"7685_CR44","doi-asserted-by":"publisher","unstructured":"Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019. https:\/\/doi.org\/10.1186\/s40425-019-0518-z.","DOI":"10.1186\/s40425-019-0518-z"},{"key":"7685_CR45","doi-asserted-by":"publisher","unstructured":"He Y, Luo W, Liu Y, Wang Y, Ma C, Wu Q et al. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci157917.","DOI":"10.1172\/jci157917"},{"key":"7685_CR46","doi-asserted-by":"publisher","unstructured":"Lu C, Zhao Y, Wang J, Shi W, Dong F, Xin Y et al. Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7\/EGFR\/AKT axis. Mol Med. 2021. https:\/\/doi.org\/10.1186\/s10020-021-00338-8.","DOI":"10.1186\/s10020-021-00338-8"},{"key":"7685_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/15384047.2021.2017222","volume":"23","author":"X Dai","year":"2022","unstructured":"Dai X, Xie Y, Dong M. Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p\/FOXO1 axis. Cancer Biol Ther. 2022;23:76\u201388.","journal-title":"Cancer Biol Ther"},{"key":"7685_CR48","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ajpath.2018.01.013","volume":"188","author":"W Liu","year":"2018","unstructured":"Liu W, Jing Z-T, Wu S-X, He Y, Lin Y-T, Chen W-N, et al. A novel AKT activator, SC79, prevents acute hepatic failure induced by Fas-mediated apoptosis of hepatocytes. Am J Pathol. 2018;188:1171\u201382.","journal-title":"Am J Pathol"},{"key":"7685_CR49","doi-asserted-by":"publisher","unstructured":"Wang Q, Zhuang X, Mu J, Deng Z-B, Jiang H, Zhang L et al. Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 2013. https:\/\/doi.org\/10.1038\/ncomms2886.","DOI":"10.1038\/ncomms2886"},{"key":"7685_CR50","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 2022;42:828\u201347.","journal-title":"Cancer Commun"},{"key":"7685_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2019.04.026","volume":"211","author":"J Lai","year":"2019","unstructured":"Lai J, Deng G, Sun Z, Peng X, Li J, Gong P, et al. Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing Blood-Brain Barrier. Biomaterials. 2019;211:48\u201356.","journal-title":"Biomaterials"},{"key":"7685_CR52","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.1016\/j.biomaterials.2012.07.046","volume":"33","author":"H Xin","year":"2012","unstructured":"Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33:8167\u201376.","journal-title":"Biomaterials"},{"key":"7685_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1164\/rccm.201503-0440SO","volume":"192","author":"S Vicent","year":"2015","unstructured":"Vicent S, Perurena N, Govindan R, Lecanda F. Bone metastases in lung cancer. potential novel approaches to therapy. Am J Respir Crit Care Med. 2015;192:799\u2013809.","journal-title":"Am J Respir Crit Care Med"},{"key":"7685_CR54","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"7685_CR55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554\u2013554.","journal-title":"Science"},{"key":"7685_CR56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606\u201319.","journal-title":"Nat Rev Genet"},{"key":"7685_CR57","doi-asserted-by":"publisher","unstructured":"Wang S, Niu X, Bao X, Wang Q, Zhang J, Lu S et al. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. Oncol Rep. 2019. https:\/\/doi.org\/10.3892\/or.2019.7080.","DOI":"10.3892\/or.2019.7080"},{"key":"7685_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","volume":"347","author":"Q Wu","year":"2014","unstructured":"Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347:159\u201366.","journal-title":"Cancer Lett"},{"key":"7685_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy. Cancer Discov. 2016;6:202\u201316.","journal-title":"Cancer Discov"},{"key":"7685_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605\u201335.","journal-title":"Cell"},{"key":"7685_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107123","volume":"202","author":"X Liu","year":"2024","unstructured":"Liu X, Mei W, Zhang P, Zeng C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities. Pharmacol Res. 2024;202:107123.","journal-title":"Pharmacol Res"},{"key":"7685_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cam4.191","volume":"3","author":"A Stjernstr\u00f6m","year":"2014","unstructured":"Stjernstr\u00f6m A, Karlsson C, Fernandez OJ, S\u00f6derkvist P, Karlsson MG, Thunell LK. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 2014;3:337\u201348.","journal-title":"Cancer Med"},{"key":"7685_CR63","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.lungcan.2023.02.023","volume":"178","author":"S Daher","year":"2023","unstructured":"Daher S, Zer A, Tschernichovsky R, Yacobi R, Barshack I, Tsabari S, et al. Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. Lung Cancer. 2023;178:229\u201336.","journal-title":"Lung Cancer"},{"key":"7685_CR64","doi-asserted-by":"publisher","unstructured":"Chong X, Chen J, Zheng N, Zhou Z, Hai Y, Chen S et al. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Mol Cancer. 2022. https:\/\/doi.org\/10.1186\/s12943-022-01531-x.","DOI":"10.1186\/s12943-022-01531-x"},{"key":"7685_CR65","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/C5MB00101C","volume":"11","author":"T Ersahin","year":"2015","unstructured":"Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K\/AKT\/mTOR interactive pathway. Mol BioSyst. 2015;11:1946\u201354.","journal-title":"Mol BioSyst"},{"key":"7685_CR66","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"7685_CR67","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.actbio.2023.07.059","volume":"169","author":"S Ma","year":"2023","unstructured":"Ma S, Li X, Mai Y, Guo J, Zuo W, Yang J. Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine. Acta Biomater. 2023;169:489\u201399.","journal-title":"Acta Biomater"},{"key":"7685_CR68","doi-asserted-by":"publisher","unstructured":"Zhao C-C, Han Q-J, Ying H-Y, Gu X-X, Yang N, Li L-Y et al. TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth. OncoImmunology. 2022. https:\/\/doi.org\/10.1080\/2162402x.2022.2032918.","DOI":"10.1080\/2162402x.2022.2032918"},{"key":"7685_CR69","doi-asserted-by":"publisher","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J et al. Targeting cancer stem cell pathways for cancer therapy. Sig Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-0110-5.","DOI":"10.1038\/s41392-020-0110-5"},{"key":"7685_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson WIII, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non\u2013small cell lung cancer. Cancer Res. 2016;76:227\u201338.","journal-title":"Cancer Res"},{"key":"7685_CR71","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1136\/gutjnl-2021-324994","volume":"71","author":"CF Ruivo","year":"2022","unstructured":"Ruivo CF, Bastos N, Adem B, Batista I, Duraes C, Melo CA, et al. Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. Gut. 2022;71:2043\u201368.","journal-title":"Gut"},{"key":"7685_CR72","doi-asserted-by":"publisher","unstructured":"Su C, Zhang J, Yarden Y, Fu L. The key roles of cancer stem cell-derived extracellular vesicles. Sig Transduct Target Ther. 2021. https:\/\/doi.org\/10.1038\/s41392-021-00499-2.","DOI":"10.1038\/s41392-021-00499-2"},{"key":"7685_CR73","doi-asserted-by":"publisher","first-page":"12226","DOI":"10.1021\/acsnano.2c02971","volume":"16","author":"R Haldavnekar","year":"2022","unstructured":"Haldavnekar R, Venkatakrishnan K, Tan B. Cancer stem cell derived extracellular vesicles with self-functionalized 3D nanosensor for real-time cancer diagnosis: eliminating the roadblocks in liquid biopsy. ACS Nano. 2022;16:12226\u201343.","journal-title":"ACS Nano"},{"key":"7685_CR74","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-08-0233","volume":"14","author":"W Yang","year":"2008","unstructured":"Yang W, Luo D, Wang S, Wang R, Chen R, Liu Y, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res. 2008;14:5494\u2013502.","journal-title":"Clin Cancer Res"},{"key":"7685_CR75","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.actbio.2022.12.021","volume":"157","author":"W Wang","year":"2023","unstructured":"Wang W, Xiong Y, Hu X, Lu F, Qin T, Zhang L, et al. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity. Acta Biomater. 2023;157:428\u201341.","journal-title":"Acta Biomater"},{"key":"7685_CR76","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-22-3558","volume":"83","author":"X Cheng","year":"2023","unstructured":"Cheng X, Sun Y, Highkin M, Vemalapally N, Jin X, Zhou B, et al. Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21\u2013CDK4\/6\u2013cyclin D1 axis to drive tumorigenesis and drug resistance. Cancer Res. 2023;83:2839\u201357.","journal-title":"Cancer Res"},{"key":"7685_CR77","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/imm.13682","volume":"170","author":"W Jiang","year":"2023","unstructured":"Jiang W, Ouyang X, Li C, Long Y, Chen W, Ji Z, et al. Targeting PI3K\u03b1 increases the efficacy of anti-PD-1 antibody in cervical cancer. Immunology. 2023;170:419\u201338.","journal-title":"Immunology"},{"key":"7685_CR78","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.3390\/ijms22126526","volume":"22","author":"MT Munir","year":"2021","unstructured":"Munir MT, Kay MK, Kang MH, Rahman MM, Al-Harrasi A, Choudhury M, et al. Tumor-associated macrophages as multifaceted regulators of breast tumor growth. IJMS. 2021;22:6526.","journal-title":"IJMS"},{"key":"7685_CR79","doi-asserted-by":"publisher","unstructured":"Zhao H, Jiang R, Zhang C, Feng Z, Wang X. LncRNA H19-rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04055-0.","DOI":"10.1186\/s12967-023-04055-0"},{"key":"7685_CR80","doi-asserted-by":"publisher","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd\u2011generation EGFR\u2011TKI resistance in advanced non\u2011small cell lung cancer (Review). Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5270.","DOI":"10.3892\/ijo.2021.5270"},{"key":"7685_CR81","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 2023;13:1556\u201371.","journal-title":"Cancer Discov"},{"key":"7685_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173090","volume":"877","author":"C Yunna","year":"2020","unstructured":"Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1\/M2 polarization. Eur J Pharm. 2020;877:173090.","journal-title":"Eur J Pharm"},{"key":"7685_CR83","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili S, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425\u201340.","journal-title":"J Cell Physiol"},{"key":"7685_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549\u201355.","journal-title":"Trends Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07685-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T20:02:09Z","timestamp":1746561729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7685"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07685-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Harbin Medical University Cancer Hospital. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"367"}}